return to results page

VAERS ID: 2272629

AGE: UNK| SEX: F|State: FR

Description

Alopecia areata; This is a spontaneous report received from a contactable reporter(s) (Physician) from the regulatory authority. Regulatory number: FR-AFSSAPS-PS20220756. A 66-year-old female patient received BNT162b2 (COMIRNATY), on 19Apr2021 as dose 2, 30 ug, single (Lot number: EW2246) intramuscular, in left arm for covid-19 immunisation; enalapril (ENALAPRIL), (ongoing) at 20 mg 1x/day, oral for hypertension; amlodipine (AMLODIPINE), at 10 mg 1x/day, oral for hypertension; rituximab (RITUXIMAB), since 19Nov2018 (Batch/Lot number: unknown), intravenous for multiple sclerosis. The patient's relevant medical history included: "Sclerosis multiple" (unspecified if ongoing), notes: Relapsing remitting followed by secondary-progressive multiple sclerosis with additional surges; "shingles" (unspecified if ongoing), notes: In the right side of the body; "asthma" (unspecified if ongoing); "hypertension" (unspecified if ongoing); "surgical management of a spinal cord meningioma" (unspecified if ongoing); "bilateral knee replacement" (unspecified if ongoing); "bilateral cataract surgery" (unspecified if ongoing); "appendectomy" (unspecified if ongoing). Concomitant medication(s) included: FAMPYRA; MOVICOL [MACROGOL 3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE]; VITAMIN D NOS; DITROPAN; ZOPICLONE. Vaccination history included: comirnaty (DOSE 1, SINGLE, Batch: EP9605, Left arm), administration date: 22Mar2021, for COVID-19 immunization. The following information was reported: ALOPECIA AREATA (hospitalization, medically significant) with onset May2021, outcome "unknown". The patient was hospitalized for alopecia areata (start date: 28Mar2022, discharge date: 30Mar2022, hospitalization duration: 2 day(s)). The patient underwent the following laboratory tests and procedures: Magnetic resonance imaging: (Jul2019) stability of brain and spinal cord lesions, notes: without contrast enhancement. The action taken for enalapril, amlodipine and rituximab was dosage not changed. Therapeutic measures were taken as a result of alopecia areata. Clinical course: On 17May2021: letter for the dermatologist "the patient presented with alopecia \ for several months, bilaterally, progressively worsening over a period of several months. There did not appear to be other associated dermatological symptoms. Rituximab seems to be one of the causes of alopecia, but we would like to see those other differential diagnoses and adapted medical care were eliminated. On 29Nov2021: booster injection of Comirnaty 1G047A left arm. On 23Mar2022: indication for corticosteroid bolus medical care for alopecia areata (Dermatologist's opinion). From 28 to 30Mar2022: Day hospital for methylprednisolone 500mg bolus for 3 days. On May2022: next course of rituximab. Discussion/conclusion of their analysis: In summary, the role of these medications (rituximab, Comirnaty, enalapril and amlodipine) cannot be excluded, the available data do not allow us to suspect rituximab more than the Comirnaty vaccine.

Symptoms

Alopecia areata, Magnetic resonance imaging

Vaccines

VAX DATE: 18 November 2018 | ONSET DATE: 30 April 2021 | DAYS TO ONSET: 894
Vaccine TypeManufacturerVaccine NameDoseRouteSiteLot
  • COVID19
  • UNK
  • PFIZERBIONTECH
  • UNKNOWN MANUFACTURER
  • COVID19 (COVID19 (PFIZER-BIONTECH))
  • VACCINE NOT SPECIFIED (NO BRAND NAME)
  • 2
  • UNK
  • OT
  • LA
  • EW2246

RECVDATE:11 May 2022
CAGE_YR:
CAGE_MO:
RPT_DATE:
DIED:
DATEDIED:
L_THREAT:
ER_VISIT:
HOSPITAL:Y
HOSPDAYS:2
X_STAY:
DISABLE:
RECOVD:U
LAB_DATA:Test Date: 201907; Test Name: Cerebral and medullar Magnetic Resonance Imaging; Result Unstructured Data: Test Result:stability of brain and spinal cord lesions; Comments: without contrast enhancement
V_ADMINBY:OTH
OTHER_MEDS:FAMPYRA; MOVICOL [MACROGOL 3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE]; DITROPAN; ZOPICLONE
CUR_ILL:
HISTORY:Medical History/Concurrent Conditions: Appendectomy; Asthma; Cataract operation; Hypertension; Knee replacement; Meningioma surgery; Sclerosis multiple (Relapsing remitting followed by secondary-progressive multiple sclerosis with additional surges); Shingles (In the right side of the body)
PRIOR_VAX:
SPLTTYPE:FRPFIZER INC202200656766
FORM_VERS:2
TODAYS_DATE:10 May 2022
BIRTH_DEFECT:
OFC_VISIT:
ER_ED_VISIT:
ALLERGIES:
V_FUNDBY:
return to results page

Questions? Comments? Bugs?
[email protected]
Due to the high volume of inquiries, please be patient with response times.

AND PLEASE read the FAQ first.

OpenVAERS is a private organization that posts publicly available CDC/FDA data of injuries reported post-vaccination. Reports are not proof of causality.